Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.80 |
| ▸ | GAA | P10253 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | USP7 | Q93009 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165713 | 0.87 | ALOX5 (0.78) | ALOX5GAAMAPTBACE1ADORA1 | |
| SCHEMBL2975663 | 0.84 | ALOX5 (0.57) | ALOX5GAAMAPTBACE1ADORA1 | |
| SCHEMBL5127843 | 0.83 | ALOX5 (0.65) | ALOX5GAAMAPTBACE1ADORA1 | |
| SCHEMBL2992223 | 0.82 | ALOX5 (0.63) | ALOX5GAAMAPTBACE1ADORA1 | |
| SCHEMBL1965930 | 0.80 | ADORA1 (0.78) | ALOX5GAAMAPTBACE1ADORA1 | |
| SCHEMBL13464312 | 0.80 | ALOX5 (0.66) | ALOX5GAAMAPTBACE1ADORA1 | |
| SCHEMBL1966263 | 0.80 | ALOX5 (0.66) | ALOX5GAAMAPTBACE1ADORA1 | |
| SCHEMBL5122721 | 0.79 | ALOX5 (0.65) | ALOX5GAAMAPTBACE1ADORA1 | |
| SCHEMBL2977837 | 0.79 | ADORA1 (0.76) | ALOX5GAAMAPTBACE1ADORA1 | |
| SCHEMBL1967579 | 0.79 | ALOX5 (0.65) | ALOX5GAAMAPTBACE1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-07-08 | — | — | US | claimed |
| WO-2008016648-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | claimed |
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-07-08 | — | — | US | disclosed |
| WO-2008016648-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | ALOX5 3248/4885GAA 820/4885MAPT 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.